Home > Publications Database > Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. > print

001     272883
005     20250127091429.0
024 7 _ |a pmc:PMC11514856
|2 pmc
024 7 _ |a 10.1186/s40164-024-00576-6
|2 doi
024 7 _ |a pmid:39468695
|2 pmid
037 _ _ |a DZNE-2024-01299
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pu, Jingjing
|b 0
245 _ _ |a Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.
260 _ _ |a London
|c 2024
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1731075428_3251
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The basic idea of modulating the immune system to better recognize and fight tumor cells has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based treatment regimens, in which the patient's own immune cells are isolated and subsequently expanded (ex vivo) and reinfused, have also contributed significantly to the development of a personalized treatment strategy. Complementing this, the unprecedented advances in ACTs as chimeric antigen receptor (CAR)-T cell therapies and their derivatives such as CAR-NK, CAR-macrophages, CAR-γδT and CAR-NKT have further maximized the therapeutic outcomes. Herein, we provide a comprehensive overview of the development of ACTs in multiple myeloma (MM) and outline how they have evolved from an experimental form to a mainstay of standard clinical settings. Besides, we provide insights into cytokine-induced killer cell (CIK) therapy, an alternative form of ACT that (as CIK or CAR-CIK) has enormous potential in the clinical spectrum of MM. We also summarize the results of the major preclinical and clinical studies of adoptive cell therapy in MM and address the current challenges (such as cytokine release syndrome (CRS) and neurotoxicity) that limit its complete success in the cancer landscape.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a CAR-NK
|2 Other
650 _ 7 |a CAR-T
|2 Other
650 _ 7 |a CIK
|2 Other
650 _ 7 |a Cell therapy
|2 Other
650 _ 7 |a Immunotherapy
|2 Other
650 _ 7 |a Multiple myeloma
|2 Other
700 1 _ |a Liu, Ting
|0 P:(DE-2719)9002571
|b 1
|e First author
|u dzne
700 1 _ |a Sharma, Amit
|b 2
700 1 _ |a Jiang, Liping
|b 3
700 1 _ |a Wei, Feng
|b 4
700 1 _ |a Ren, Xiubao
|b 5
700 1 _ |a Schmidt-Wolf, Ingo G H
|b 6
700 1 _ |a Hou, Jian
|b 7
773 _ _ |a 10.1186/s40164-024-00576-6
|g Vol. 13, no. 1, p. 105
|0 PERI:(DE-600)2669066-4
|n 1
|p 105
|t Experimental hematology & oncology
|v 13
|y 2024
|x 2162-3619
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272883/files/DZNE-2024-01299.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272883/files/DZNE-2024-01299.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272883
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002571
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-22
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXP HEMATOL ONCOL : 2022
|d 2023-08-22
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EXP HEMATOL ONCOL : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:21Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-22
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-22
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
920 1 _ |0 I:(DE-2719)1013005
|k AG Ehninger
|l Translational Biogerontology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21